KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Asset Writedowns and Impairment (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $209000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Asset Writedowns and Impairment changed N/A year-over-year to $209000.0, compared with a TTM value of $209000.0 through Mar 2025, down 84.07%, and an annual FY2025 reading of $985000.0, changed N/A over the prior year.
  • Asset Writedowns and Impairment was $209000.0 for Q1 2025 at Biocryst Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.4 million in Q3 2024 and bottomed at -$1.4 million in Q4 2024.
  • Average Asset Writedowns and Impairment over 3 years is $219625.0, with a median of $105500.0 recorded in 2023.
  • Peak annual rise in Asset Writedowns and Impairment hit 68100.0% in 2024, while the deepest fall reached 203.73% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at $1.3 million in 2023, then plummeted by 203.73% to -$1.4 million in 2024, then skyrocketed by 115.36% to $209000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for BCRX at $209000.0 in Q1 2025, -$1.4 million in Q4 2024, and $1.4 million in Q3 2024.